Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib plus pegylated interferon alfa-2b in CML with persistent molecular residual disease after long-term imatinib
NL-OMON41622Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Sep 2013
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib and peginterferon alfa-2b in chronic myelogenous leukemia (CML), sponsored by Vrije University Medical Center. Primary endpoints: Confirmed MR4.0 at Month 12, Predictive immune cell subsets for response and 5 more. Started Sep 2013; status: active, not recruiting.
02
Drugs
nilotinibpeginterferon alfa-2b
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON41622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41622.